Patents Assigned to RESOLVE THERAPEUTICS, LLC
  • Therapeutic nuclease-albumin fusions and methods
    Patent number: 10988745
    Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: April 27, 2021
    Assignee: RESOLVE THERAPEUTICS, LLC
    Inventors: James Arthur Posada, Chris Gabel